Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9C030
UPID:
TRIM6_HUMAN
Alternative names:
RING finger protein 89; RING-type E3 ubiquitin transferase TRIM6
Alternative UPACC:
Q9C030; A8K2A7; B4DDQ5; Q86WZ8; Q9HCR1
Background:
Tripartite motif-containing protein 6 (TRIM6), also known as RING finger protein 89, is a pivotal E3 ubiquitin ligase. It orchestrates the activation of the IKBKE-dependent branch of the type I interferon signaling pathway, crucial for antiviral responses. TRIM6, in collaboration with UBE2K, generates 'Lys-48'-linked polyubiquitin chains, facilitating IKBKE oligomerization and autophosphorylation. Additionally, it ubiquitinates MYC, regulating embryonic stem cell pluripotency, and enhances RIGI-mediated antiviral immune responses by promoting 'Lys-48'-polyubiquitin chain association with DHX16.
Therapeutic significance:
Understanding the role of Tripartite motif-containing protein 6 could open doors to potential therapeutic strategies.